Chelsea Therapeutics, Inc. Achieves Target Enrollment in Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension

CHARLOTTE, N.C., June 30, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has successfully reached its target enrollment of 82 patients for Study 302, the first of two pivotal Phase III clinical trials in Chelsea’s registration program of Droxidopa for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH).

MORE ON THIS TOPIC